Farletuzumab Fails to Improve Survival in Ovarian Cancer

Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.
Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.

Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer, a study published in the Journal of Clinical Oncology has shown.1

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly expressed in ovarian carcinoma but largely absent from normal tissue.

For the double-blind, phase 3 trial, researchers enrolled 1100 women with ovarian cancer who had their first recurrence 6 to 24 months following completion of platinum-taxane chemotherapy.

All patients received carboplatin plus paclitaxel or docetaxel for 6 cycles. Patients were also randomly assigned 1:1:1 to also receive farletuzumab 1.25 mg/kg, farletuzumab 2.5 mg/kg, or placebo, which was continued weekly as a single-agent until disease progression.

Results showed that progression-free survival was 9.0 months with farletuzumab 1.25 mg/kg, 9.5 months with farletuzumab 2.5 mg/kg, and 9.7 months with placebo. Researchers found that there was no statistically significant difference between the farletuzumab 1.25 mg/kg group and placebo (HR, 0.99; 95% CI: 0.81-1.21) or the 2.5 mg/kg group and placebo (HR, 0.86; 95% CI: 0.70-1.06).

The study also demonstrated that in a prespecified subgroup, baseline levels of CA-125, a biomarker for ovarian cancer, not more than 3 times the upper limit of normal were associated with longer progression-free survival (HR, 0.49; P = .0028) and overall survival (HR, 0.44; P = .0108) for farletuzumab 2.5 mg/kg compared with placebo.

In terms of safety, the most frequently reported adverse events were those associated with chemotherapy.

REFERENCE

1. Vergote I, Armstrong D, Scambia G, et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse [published online ahead of print March 21, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.63.2596.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs